No Data
No Data
Morgan Stanley Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $72
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Raises Target Price to $60
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Rhythm Pharmaceuticals (RYTM) and Lyell Immunopharma (LYEL)
Rhythm Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $65
Express News | RPT-Rhythm Pharmaceuticals: Plan to Initiate New Phase 2 Trial Exploring Setmelanotide in Prader-Willi Syndrome